Jagsonpal Pharmaceuticals Limited
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- ₹341.95
- Today's High:
- ₹354.45
- Open Price:
- ₹349.95
- 52W Low:
- ₹254
- 52W High:
- ₹420.2
- Prev. Close:
- ₹348.8
- Volume:
- 9354
Company Statistics
- Market Cap.:
- ₹9.06 billion
- Book Value:
- 52.661
- Revenue TTM:
- ₹2.41 billion
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- ₹1.30 billion
- Profit Margin:
- 0%
- Return on Assets TTM:
- 0%
- Return on Equity TTM:
- 0%
Company Profile
Jagsonpal Pharmaceuticals Limited had its IPO on under the ticker symbol JAGSNPHARM.
The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Jagsonpal Pharmaceuticals Limited has a staff strength of 0 employees.
Stock update
Shares of Jagsonpal Pharmaceuticals Limited opened at ₹349.95 at the start of the last trading session i.e. 2023-05-28.
The stocks traded within a range of ₹341.95 - ₹354.45, and closed at ₹344.85.
This is a -1.13% slip from the previous day's closing price.
A total volume of 9,354 shares were traded at the close of the day’s session.
In the last one week, shares of Jagsonpal Pharmaceuticals Limited have slipped by -1.95%.
Jagsonpal Pharmaceuticals Limited's Key Ratios
Jagsonpal Pharmaceuticals Limited has a market cap of ₹9.06 billion, indicating a price to book ratio of 6.8826 and a price to sales ratio of 4.05.
In the last 12-months Jagsonpal Pharmaceuticals Limited’s revenue was ₹2.41 billion with a gross profit of ₹1.30 billion and an EBITDA of ₹312.46 million. The EBITDA ratio measures Jagsonpal Pharmaceuticals Limited's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Jagsonpal Pharmaceuticals Limited’s operating margin was 0% while its return on assets stood at 0% with a return of equity of 0%.
In Q1, Jagsonpal Pharmaceuticals Limited’s quarterly earnings growth was a positive 44.2% while revenue growth was a positive 10.4%.
Jagsonpal Pharmaceuticals Limited’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 41.3321
- PEG
Its diluted EPS in the last 12-months stands at ₹8.37 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Jagsonpal Pharmaceuticals Limited’s profitability.
Jagsonpal Pharmaceuticals Limited stock is trading at a EV to sales ratio of 3.8197 and a EV to EBITDA ratio of 32.3563. Its price to sales ratio in the trailing 12-months stood at 4.05.
Jagsonpal Pharmaceuticals Limited stock pays annual dividends of ₹0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- ₹1.95 billion
- Total Liabilities
- ₹275.72 million
- Operating Cash Flow
- ₹0
- Capital Expenditure
- ₹0
- Dividend Payout Ratio
- 0%
Jagsonpal Pharmaceuticals Limited ended 2023 with ₹1.95 billion in total assets and ₹0 in total liabilities. Its intangible assets were valued at ₹1.95 billion while shareholder equity stood at ₹1.59 billion.
Jagsonpal Pharmaceuticals Limited ended 2023 with ₹0 in deferred long-term liabilities, ₹275.72 million in other current liabilities, in common stock, ₹0 in retained earnings and ₹0.00 in goodwill. Its cash balance stood at ₹110.53 million and cash and short-term investments were ₹0. The company’s total short-term debt was ₹0 while long-term debt stood at ₹0.
Jagsonpal Pharmaceuticals Limited’s total current assets stands at ₹1.65 billion while long-term investments were ₹0 and short-term investments were ₹1.04 billion. Its net receivables were ₹208.72 million compared to accounts payable of ₹163.63 million and inventory worth ₹206.76 million.
In 2023, Jagsonpal Pharmaceuticals Limited's operating cash flow was ₹0 while its capital expenditure stood at ₹0.
Comparatively, Jagsonpal Pharmaceuticals Limited paid ₹0 in dividends in 2023.
Other key metrics
- Current Trading Price
- ₹344.85
- 52-Week High
- ₹420.2
- 52-Week Low
- ₹254
- Analyst Target Price
- ₹
Jagsonpal Pharmaceuticals Limited stock is currently trading at ₹344.85 per share. It touched a 52-week high of ₹420.2 and a 52-week low of ₹420.2. Analysts tracking the stock have a 12-month average target price of ₹.
Its 50-day moving average was ₹329.58 and 200-day moving average was ₹348.18 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 7841.8% of the company’s stock are held by insiders while 9.8% are held by institutions.
Frequently Asked Questions About Jagsonpal Pharmaceuticals Limited
Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)
Most Active
Top Gainers
Top Losers
About
Jagsonpal Pharmaceuticals Limited develops and manufactures bulk drugs and pharmaceutical formulations in the areas of women health, pain and analgesics, and general medicine. It offers general medicines, such as allergy management, immunity and cell protection, gut and mind management, anti-infectives, and dentist and ENT range products; and women’s healthcare products, including pregnancy care, and dysfunctional uterine bleeding complications and management products. The company also provides pain and analgesics products in the areas of pain management, and bone and joint care. It offers drugs in the form of tablets, capsules, and syrups. The company was founded in 1964 and is headquartered in New Delhi, India. Jagsonpal Pharmaceuticals Limited is a subsidiary of Aresko Progressive Private Limited.